Vanguard Group Inc. Buys 676,865 Shares of Oruka Therapeutics, Inc. $ORKA

Vanguard Group Inc. lifted its stake in shares of Oruka Therapeutics, Inc. (NASDAQ:ORKA) by 38.1% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 2,453,530 shares of the company’s stock after acquiring an additional 676,865 shares during the quarter. Vanguard Group Inc. owned approximately 5.07% of Oruka Therapeutics worth $74,366,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds also recently made changes to their positions in the company. Legal & General Group Plc bought a new position in shares of Oruka Therapeutics during the second quarter worth about $28,000. BNP Paribas Financial Markets grew its stake in Oruka Therapeutics by 464.0% during the second quarter. BNP Paribas Financial Markets now owns 2,803 shares of the company’s stock worth $31,000 after purchasing an additional 2,306 shares during the period. PNC Financial Services Group Inc. acquired a new stake in Oruka Therapeutics during the third quarter worth approximately $39,000. Russell Investments Group Ltd. acquired a new stake in Oruka Therapeutics during the third quarter worth approximately $43,000. Finally, Mirae Asset Global Investments Co. Ltd. grew its stake in Oruka Therapeutics by 62.4% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,352 shares of the company’s stock worth $71,000 after purchasing an additional 904 shares during the period. 56.44% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several research firms recently commented on ORKA. Leerink Partners set a $120.00 target price on Oruka Therapeutics in a research note on Thursday, April 30th. Wedbush set a $165.00 target price on Oruka Therapeutics in a research note on Monday, April 27th. Guggenheim set a $200.00 target price on Oruka Therapeutics and gave the stock a “buy” rating in a research note on Monday, April 27th. Stifel Nicolaus raised their target price on Oruka Therapeutics from $47.00 to $72.00 and gave the stock a “buy” rating in a research note on Friday, March 13th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Oruka Therapeutics in a research note on Tuesday, April 21st. Ten equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $120.80.

Oruka Therapeutics Price Performance

ORKA opened at $63.90 on Friday. Oruka Therapeutics, Inc. has a fifty-two week low of $8.91 and a fifty-two week high of $91.00. The firm has a market capitalization of $3.21 billion, a PE ratio of -32.94 and a beta of -0.20. The company’s 50-day moving average is $54.63 and its 200 day moving average is $39.18.

Oruka Therapeutics (NASDAQ:ORKA) last posted its earnings results on Wednesday, May 13th. The company reported ($0.48) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.52) by $0.04. As a group, analysts expect that Oruka Therapeutics, Inc. will post -2.2 EPS for the current year.

Insider Transactions at Oruka Therapeutics

In related news, insider Joana Goncalves sold 7,000 shares of Oruka Therapeutics stock in a transaction that occurred on Wednesday, April 15th. The stock was sold at an average price of $66.12, for a total transaction of $462,840.00. Following the transaction, the insider owned 33,377 shares of the company’s stock, valued at $2,206,887.24. The trade was a 17.34% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Lawrence Otto Klein sold 1,729 shares of Oruka Therapeutics stock in a transaction that occurred on Monday, March 16th. The shares were sold at an average price of $41.30, for a total value of $71,407.70. Following the transaction, the chief executive officer directly owned 927,309 shares in the company, valued at approximately $38,297,861.70. The trade was a 0.19% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 23,765 shares of company stock worth $1,089,745 in the last 90 days. 23.49% of the stock is currently owned by company insiders.

Oruka Therapeutics Profile

Oruka Therapeutics, Inc is a clinical?stage biopharmaceutical company focused on the development of novel peptide?based therapies for oncology. The company’s proprietary stapled peptide platform is designed to selectively disrupt intracellular protein–protein interactions that drive tumor growth and immune evasion. By combining the specificity of biologics with the cell?permeability of small molecules, Oruka aims to target cancer pathways that have been historically considered “undruggable.”

The company’s lead candidate, ONCT-01, is currently in Phase 1 clinical trials for patients with advanced solid tumors, assessing safety, tolerability and preliminary efficacy.